Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFutura Medical Regulatory News (FUM)

Share Price Information for Futura Medical (FUM)

Share Price is delayed by 15 minutes
Get Live Data
0.546    -0.034 (-5.86%)
Bid:
0.55
Ask:
0.60
Spread: 0.05 (9.091%)
Market Cap: £3.17m
FUM Live PriceLast checked at - London Stock Exchange

Intraday Futura Medical Share Chart

AGM Statement

24 Jun 2019 16:42

RNS Number : 2473D
Futura Medical PLC
24 June 2019
 

Results of Annual General Meeting

24 June 2019

Futura Medical plc (AIM: FUM) ("Futura" or the "Company"), a pharmaceutical company developing a portfolio of innovative products based on its proprietary, transdermal Dermasys® drug delivery technology currently focused on sexual health and pain, announces that at its Annual General Meeting, held earlier today, all resolutions were duly passed by the shareholders.

 

For further information please contact:

Futura Medical plc James Barder, Chief ExecutiveAngela Hildreth, Finance Director and COO

Email: Investor.relations@futuramedical.comTel: +44 (0) 1483 685 670

Nominated Adviser and Sole Broker:LiberumBidhi Bhoma/ Euan Brown/ Kane CollingsTel: +44 (0) 203 100 2000

 

For media enquiries please contact:

Optimum Strategic Communications

Mary Clark/ Eva Haas/ Hollie Vile

Email: futuramedical@optimumcomms.com

Tel: +44 (0) 203 950 9144

 

Notes to editors:

 

About Futura Medical plc

Futura Medical plc (AIM: FUM), is a pharmaceutical company developing a portfolio of innovative products based on its proprietary, transdermal Dermasys® drug delivery technology. These products are optimised for clinical efficacy, safety, administration and patient convenience and are developed for the prescription and consumer healthcare markets as appropriate. Current therapeutic areas are sexual health, including erectile dysfunction, and pain relief. Development and commercialisation strategies are designed to maximise product differentiation and value creation whilst minimising risk.

 

The first European Phase 3 study for MED2005, referred to as "FM57", is a 1,000 patient, dose-ranging, multi-centre, randomised, double blind, placebo-controlled, home use, parallel group study of MED2005 0.2%, 0.4% and 0.6% Glyceryl Trinitrate for the treatment of erectile dysfunction with an open label extension. FM57 is progressing on track, with headline data expected by the end of 2019.

 

Futura is based in Guildford, Surrey, and its shares trade on the AIM market of the London Stock Exchange. www.futuramedical.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
RAGCKQDNPBKDFAB
Date   Source Headline
19th Sep 20087:00 amRNSInterim Results
5th Sep 20087:00 amRNSNotice of Interim Results
7th May 20087:00 amRNSAGM Statement
9th Apr 20087:00 amRNSProject Update
3rd Apr 20087:00 amRNSAnnual Report and AGM Notice
31st Mar 20087:01 amRNSBoard Change
25th Mar 20087:01 amRNSAnnual Report and Accounts
13th Mar 20087:00 amRNSPreliminary Results
4th Mar 20087:01 amRNSNotification of Results
16th Jan 200812:31 pmRNSMajor Interest in Shares
10th Jan 20088:00 amRNSDirector's Share Transfer
3rd Jan 20088:00 amRNSDirector's Share Transfer
7th Dec 20077:00 amRNSLong Term Incentive Scheme
15th Nov 20077:01 amRNSIssue of Equity
24th Sep 20077:02 amRNSInterim Results
18th Sep 20077:00 amRNSNotice of Results
17th Sep 20079:08 amRNSMED2002 Licensing Deal
23rd Aug 20077:00 amRNSAppt of Pain Relief Adviser
14th Aug 20071:31 pmRNSHolding(s) in Company
9th Aug 20077:01 amRNSPositive Study Results
2nd Aug 20073:59 pmRNSHoldings in Company
27th Jul 20077:00 amRNSGrant Approval
19th Jul 20077:00 amRNSResult of AGM
20th Jun 20077:02 amRNSAnnual Report & Accounts
30th May 20077:02 amRNSFinal Results
25th May 200710:33 amRNSNotice of Preliminary Results
17th May 20077:01 amRNSHolding(s) in Company
14th May 20077:02 amRNSMED2002 Update
9th May 20077:02 amRNSCSD500 Patents granted
4th May 20077:01 amRNSConference Presentation
18th Apr 20077:01 amRNSDermaSys Agreement with GSK
22nd Mar 200711:02 amRNSHolding(s) in Company
20th Mar 20077:01 amRNSHolding(s) in Company
28th Feb 20077:01 amRNSLaunch of DermaSys Brand
31st Jan 20078:00 amRNSAdditional Listing
18th Jan 200712:52 pmRNSHolding(s) in Company
20th Dec 20067:01 amRNSTotal Voting Rights
16th Nov 20067:01 amRNSCSD500 Regulatory Update
12th Oct 20067:00 amRNSTechnical Seminar
21st Sep 20067:01 amRNSInterim Results
7th Sep 20067:00 amRNSNotice of Interim Results
6th Sep 20067:01 amRNSDCF100 Skin Study Results
17th Jul 20067:00 amRNSFLD500 Scale-up Trials
6th Jul 20067:01 amRNSNew Product Update
4th Jul 20062:44 pmRNSIssue of Equity
4th Jul 20062:39 pmRNSAgreement with GSK
27th Jun 20061:01 pmRNSHolding(s) in Company
21st Jun 200611:13 amRNSComment on Press Speculation
22nd May 20067:01 amRNSPreliminary Results
9th May 20067:00 amRNSUpdate on MED2002

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.